Amphastar receives fda approval for vasopressin

Rancho cucamonga, ca / accesswire / july 19, 2022 / amphastar pharmaceuticals, inc. (nasdaq:amph) announced that the u.s. food and drug administration ("fda") has approved the company's abbreviated new drug application ("anda") for vasopressin injection, usp 20 units/ml, 1ml single dose vial. in december 2021, the company had received fda tentative approval for the anda.
AMPH Ratings Summary
AMPH Quant Ranking